Baicalein resensitizes tamoxifen‐resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia‐inducible factor‐1α

Drug resistance is a major hurdle for the effectiveness of tamoxifen (TAM) to provide clinical benefit. Therefore, it is essential to identify a sensitizer that could be used to improve TAM efficacy in treating TAM‐resistant breast cancer. Here, we investigated the ability of baicalein to reverse TA...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yan, Zhang, Jingyu, Zhang, Minqin, Song, Yuxuan, Zhang, Yue, Fan, Shuangqin, Ren, Shuang, Fu, Lingyun, Zhang, Nenling, Hui, Hui, Shen, Xiangchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567056/
https://www.ncbi.nlm.nih.gov/pubmed/34841716
http://dx.doi.org/10.1002/ctm2.577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567056/
https://www.ncbi.nlm.nih.gov/pubmed/34841716
http://dx.doi.org/10.1002/ctm2.577

Ejemplares similares